ReviewCombinatorial chemistry & high throughput screening2026
Review of Nanomedicine Research Proposals Received at ICMR: Gaps in Research and Further Opportunities.
Review in Combinatorial chemistry & high throughput screening, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionNanomedicine integrates nanotechnology with healthcare, offering targeted diagnostics, therapeutic solutions, and preventive applications. India, through agencies such as the Indian Council of Medical Research (ICMR), the Department of Biotechnology (DBT), and the Department of Science & Technology (DST), has prioritized nanomedicine to address public health challenges. Despite significant progress, gaps persist in clinical translation and interdisciplinary applications.
objectiveTo analyze the scope, gaps, and opportunities in nanomedicine research in India, focusing on ICMR-funded projects.
methodsData on nanomedicine proposals submitted to ICMR (2018-2022) were reviewed using keyword-based searches from databases and survey responses from principal investigators. Metrics included funding trends, research objectives, and outcomes. Quantitative and qualitative analyses assessed scientific progress and translational potential.
resultsOver the past five years, the ICMR has funded over 250 projects, with a focus on cancer therapy, infectious diseases, and diagnostics. Achievements include nanoparticle-based drug delivery systems and diagnostics, with notable innovations like Albupax® and gold nanoparticlebased sensors. Research activity increased over the years, with a slight slowdown during the COVID-19 period. Funding was primarily allocated to states with established research infrastructures, underscoring the need for more equitable support nationwide. DISCUSSION: Nanomedicine research in India has made significant progress, primarily in cancer; however, limited research has been observed in non-cancer applications and long-term safety studies. Differences in funding across various regions and difficulties in turning ideas into marketable products were major problems. Integrating nanomedicine with genetic tools offers promise for more targeted treatments.
conclusionThe ICMR's support has advanced nanomedicine research in India, particularly in the field of oncology. To strengthen India's position in the field, future efforts must address unmet needs, including non-cancer applications, clinical translation, and regulatory harmonization. Collaborative initiatives and equitable funding distribution can accelerate advancements and strengthen the implementation of nanomedicine research.
Indexed as
Identifiers
40685732What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.